Cerus Co. (NASDAQ:CERS – Get Rating)'s share price gapped up prior to trading on Wednesday . The stock had previously closed at $3.83, but opened at $3.98. Cerus shares last traded at $3.93, with a volume of 6,873 shares changing hands.

Analyst Upgrades and Downgrades

CERS has been the subject of a number of research analyst reports. StockNews.com began coverage on shares of Cerus in a report on Wednesday, October 12th. They issued a "hold" rating for the company. BTIG Research dropped their target price on shares of Cerus to $6.00 in a report on Tuesday, November 15th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Cerus in a research note on Monday, December 5th.

Cerus Trading Down 0.7 %

The company has a debt-to-equity ratio of 0.37, a current ratio of 1.73 and a quick ratio of 1.44. The business has a 50-day moving average price of $3.82 and a two-hundred day moving average price of $4.41. The firm has a market cap of $727.43 million, a PE ratio of -18.64 and a beta of 1.08.

Insider Activity at Cerus

In other news, Director Daniel N. Swisher, Jr. sold 12,500 shares of the business's stock in a transaction on Thursday, November 10th. The stock was sold at an average price of $3.91, for a total value of $48,875.00. Following the completion of the transaction, the director now directly owns 113,808 shares of the company's stock, valued at $444,989.28. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 7.33% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Cerus

Institutional investors have recently modified their holdings of the company. MQS Management LLC purchased a new stake in Cerus in the 3rd quarter worth approximately $159,000. Bank of New York Mellon Corp grew its position in shares of Cerus by 9.4% in the third quarter. Bank of New York Mellon Corp now owns 631,907 shares of the biotechnology company's stock valued at $2,275,000 after purchasing an additional 54,494 shares during the period. Robeco Institutional Asset Management B.V. acquired a new position in Cerus in the third quarter valued at $87,000. Capital Impact Advisors LLC acquired a new position in Cerus in the third quarter valued at $49,000. Finally, Tamarack Advisers LP lifted its position in Cerus by 21.3% during the third quarter. Tamarack Advisers LP now owns 2,425,000 shares of the biotechnology company's stock worth $8,730,000 after buying an additional 425,000 shares during the period. Institutional investors and hedge funds own 82.47% of the company's stock.

Cerus Company Profile

(Get Rating)

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Featured Articles

• Get a free copy of the StockNews.com research report on Cerus (CERS)
• Your Decision to Buy Palantir May Simply Be a Matter of Time
• Are Caterpillar and Deere Setting Up to Rally in 2023?
• Mullen Automotive Gets a Jolt as the I-GO Arrives in Europe
• Will The Sun Shine On These 3 Large-Cap Solar Stocks In 2023?
• Lucid Motors Faces a Reality That May Cloud a Bullish Perception

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.